Back to top
more

Synlogic (SYBX)

(Delayed Data from NSDQ)

$1.91 USD

1.91
66,030

+0.04 (1.87%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $1.91 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 10.45% and 2.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 21.74% and 39.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 10.34% and 12.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of 0% and 1.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

What Makes Synlogic, Inc. (SYBX) a New Buy Stock

by Zacks Equity Research

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU

by Zacks Equity Research

AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.

Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU

by Zacks Equity Research

Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

by Zacks Equity Research

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

by Zacks Equity Research

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.